Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00807560
Other study ID # GCO 07-0216
Secondary ID 1R21HD057394-01
Status Completed
Phase Phase 1/Phase 2
First received December 11, 2008
Last updated December 2, 2015
Start date September 2008
Est. completion date June 2013

Study information

Verified date December 2015
Source Icahn School of Medicine at Mount Sinai
Contact n/a
Is FDA regulated No
Health authority United States: Institutional Review Board
Study type Interventional

Clinical Trial Summary

The purpose of this study is to determine whether a parent/guardian intervention for adolescent overweight/obesity more effective than a nutritional counseling education curriculum for reducing body mass index z-score (BMI Z-score) and related outcomes.


Description:

Rates of pediatric overweight (PO) among Americans are increasing and associated with significant psychological, social, quality of life, and health related outcomes. Because of the broad mental and physical health implications of PO and the difficulty in sustaining weight loss as an adult, it is of interest to find successful methods of weight loss and/or prevention of weight gain for obese children and adolescents. The family unit is a logical and empirically supported point of intervention for PO. Interventions on this level have shown good long term efficacy in young children, but there is very little research on adolescent family intervention. Within the eating disorder literature, there is growing support for the efficacy of family-based interventions (FBI) for adolescents. Given its trans-developmental applicability, focus on family as the unit of intervention, and utility in creating a healthy eating environment, FBI is a logical candidate for adaptation to intervention for PO and intervention for at-risk for overweight youth (FBI-PO). The core of the current project is to test the feasibility and efficacy of an adapted FBI manual for adolescent overweight and at-risk for overweight in an outpatient eating and weight disorders clinic and compare this modality to a minimal nutritional educational control (NEC) condition.


Recruitment information / eligibility

Status Completed
Enrollment 77
Est. completion date June 2013
Est. primary completion date June 2013
Accepts healthy volunteers No
Gender Both
Age group 13 Years to 17 Years
Eligibility Inclusion Criteria:

- Ages 13-17

- Male and female

- Living with at least one parent or guardian who is willing to participate in treatment

- A BMI percentile >85% for gender and age (e.g., overweight or at risk for overweight)

Exclusion Criteria:

- Current psychotic illness

- Current alcohol/drug dependence

- Active suicidality

- Eating disorders (e.g., binge eating disorder)

- History of bariatric surgery

- Medication associated with significant weight changes (e.g., antipsychotics)

- Serious medical or physical conditions resulting in significant weight changes (e.g., pregnancy, genetic disorders).

- Complications of obesity that contraindicate moderate physical activity (e.g. orthopedic disorders)

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Behavioral:
FBT-PO
The goal of FBT-PO is to resolve the eating disorder and return the patient to healthy psychosocial and physiological developmental trajectories through active family involvement across three treatment phases.
NEC
Families assigned to NEC will receive a minimal nutrition and physical activity education curriculum across 16 sessions over 24 weeks.

Locations

Country Name City State
United States The University of Chicago Chicago Illinois
United States Icahn School of Medicine at Mount Sinai NY New York

Sponsors (2)

Lead Sponsor Collaborator
Icahn School of Medicine at Mount Sinai Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary BMI Z Score Z-score was calculated using the Baylor College of Medicine Children's Nutrition Research Center's online BMI calculator (https://www.bcm.edu/research/centers/childrens-nutrition-research-center/bodycomp/bmiz2.html). baseline No
Primary BMI Z Score Z-score was calculated using the Baylor College of Medicine Children's Nutrition Research Center's online BMI calculator (https://www.bcm.edu/research/centers/childrens-nutrition-research-center/bodycomp/bmiz2.html) up to 44 weeks No
Secondary Percent Completion Percent of participants who completed the trial to assess feasibility and retention in the trial at 44 weeks No
Secondary Waist Measurement Waist measurement in inches. This is not a primary outcome variable. baseline No
Secondary Waist Measurement Waist measurement in inches. This is not a primary outcome variable. up to 44 weeks No
Secondary Hip Measurement Hip measurement in inches. This is not a primary outcome variable. baseline No
Secondary Hip Measurement Hip measurement in inches. This is not a primary outcome variable. up to 44 weeks No
Secondary Height This variable informs the calculation of the outcome variable of BMI Z score. Baseline No
Secondary Height This variable informs the calculation of the outcome variable of BMI Z score. up to 44 weeks No
Secondary Weight This variable informs the calculation for the outcome variable of BMI Z score. baseline No
Secondary Weight This variable informs the calculation of the outcome variable of BMI z score. up to 44 weeks No
Secondary BMI Body Mass Index: this variable informs the calculation of the outcome variable of BMI z-score. baseline No
Secondary BMI Body Mass Index: this variable informs the calculation of the primary outcome variable of BMI z-score. up to 44 weeks No
Secondary BMI Percentile Body Mass Index percentile. This is not a primary outcome variable. baseline No
Secondary BMI Percentile Body Mass Index percentile. This is not a primary outcome variable. up to 44 weeks No
See also
  Status Clinical Trial Phase
Recruiting NCT04101669 - EndoBarrier System Pivotal Trial(Rev E v2) N/A
Recruiting NCT04243317 - Feasibility of a Sleep Improvement Intervention for Weight Loss and Its Maintenance in Sleep Impaired Obese Adults N/A
Terminated NCT03772886 - Reducing Cesarean Delivery Rate in Obese Patients Using the Peanut Ball N/A
Completed NCT03640442 - Modified Ramped Position for Intubation of Obese Females. N/A
Completed NCT04506996 - Monday-Focused Tailored Rapid Interactive Mobile Messaging for Weight Management 2 N/A
Recruiting NCT06019832 - Analysis of Stem and Non-Stem Tibial Component N/A
Active, not recruiting NCT05891834 - Study of INV-202 in Patients With Obesity and Metabolic Syndrome Phase 2
Active, not recruiting NCT05275959 - Beijing (Peking)---Myopia and Obesity Comorbidity Intervention (BMOCI) N/A
Recruiting NCT04575194 - Study of the Cardiometabolic Effects of Obesity Pharmacotherapy Phase 4
Completed NCT04513769 - Nutritious Eating With Soul at Rare Variety Cafe N/A
Withdrawn NCT03042897 - Exercise and Diet Intervention in Promoting Weight Loss in Obese Patients With Stage I Endometrial Cancer N/A
Completed NCT03644524 - Heat Therapy and Cardiometabolic Health in Obese Women N/A
Recruiting NCT05917873 - Metabolic Effects of Four-week Lactate-ketone Ester Supplementation N/A
Active, not recruiting NCT04353258 - Research Intervention to Support Healthy Eating and Exercise N/A
Completed NCT04507867 - Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III N/A
Recruiting NCT03227575 - Effects of Brisk Walking and Regular Intensity Exercise Interventions on Glycemic Control N/A
Completed NCT01870947 - Assisted Exercise in Obese Endometrial Cancer Patients N/A
Recruiting NCT06007404 - Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
Recruiting NCT05972564 - The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function Phase 1/Phase 2
Recruiting NCT05371496 - Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction Phase 2